Vigilance on NSAIDs as DOAC use rises

Doctors need to be vigilant to the risk of bleeding with DOACs, particularly in patients who are taking other medicines that might increase bleeding risk, researchers warn. Writing in this week’s MJA the research team from Adelaide Hospital said that since dabigatran, rivaroxaban and apixaban had become available on the PBS around 4000 veterans were ...

Already a member?

Login to keep reading.

© 2022 the limbic